Literature DB >> 9420270

Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.

A D Smith1, S C Geisler, A A Chen, D A Resnick, B M Roy, P J Lewi, E Arnold, G F Arnold.   

Abstract

In an effort to develop a useful AIDS vaccine or vaccine component, we have generated a combinatorial library of chimeric viruses in which the sequence IGPGRAFYTTKN from the V3 loop of the MN strain of human immunodeficiency virus type 1 (HIV-1) is displayed in many conformations on the surface of human rhinovirus 14 (HRV14). The V3 loop sequence was inserted into a naturally immunogenic site of the cold-causing HRV14, bridged by linkers consisting of zero to three randomized amino acids on each side. The library of chimeric viruses obtained was subjected to a variety of immunoselection schemes to isolate viruses that provided the most useful presentations of the V3 loop sequence for potential use in a vaccine against HIV. The utility of the presentations was assessed by measures of antigenicity and immunogenicity. Most of the immunoselected chimeras examined were potently neutralized by each of the four different monoclonal anti-V3 loop antibodies tested. Seven of eight chimeric viruses were able to elicit neutralizing antibody responses in guinea pigs against the MN and ALA-1 strains of HIV-1. Three of the chimeras elicited HIV neutralization titers that exceeded those of all but a small number of previously described HIV immunogens. These results indicate that HRV14:HIV-1 chimeras may serve as useful immunogens for stimulating immunity against HIV-1. This method can be used to flexibly reconstruct varied immunogens on the surface of a safe and immunogenic vaccine vehicle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9420270      PMCID: PMC109419     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Experimental vaccine protection against feline immunodeficiency virus.

Authors:  J K Yamamoto; T Okuda; C D Ackley; H Louie; E Pembroke; H Zochlinski; R J Munn; M B Gardner
Journal:  AIDS Res Hum Retroviruses       Date:  1991-11       Impact factor: 2.205

2.  Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

Authors:  N Almond; K Kent; M Cranage; E Rud; B Clarke; E J Stott
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

3.  HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.

Authors:  C Bruck; C Thiriart; L Fabry; M Francotte; P Pala; O Van Opstal; J Culp; M Rosenberg; M De Wilde; P Heidt; J Heeney
Journal:  Vaccine       Date:  1994-09       Impact factor: 3.641

4.  Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Authors:  J E Clements; R C Montelaro; M C Zink; A M Amedee; S Miller; A M Trichel; B Jagerski; D Hauer; L N Martin; R P Bohm
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.

Authors:  M C Gauduin; J T Safrit; R Weir; M S Fung; R A Koup
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

6.  Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

Authors:  S L Hu; K Abrams; G N Barber; P Moran; J M Zarling; A J Langlois; L Kuller; W R Morton; R E Benveniste
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

7.  Local and global structural properties of the HIV-MN V3 loop.

Authors:  P Catasti; J D Fontenot; E M Bradbury; G Gupta
Journal:  J Biol Chem       Date:  1995-02-03       Impact factor: 5.157

8.  Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

Authors:  M Girard; B Meignier; F Barré-Sinoussi; M P Kieny; T Matthews; E Muchmore; P L Nara; Q Wei; L Rimsky; K Weinhold
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1.

Authors:  D A Resnick; A D Smith; S C Gesiler; A Zhang; E Arnold; G F Arnold
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

10.  A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  T Ohno; M Terada; Y Yoneda; K W Shea; R F Chambers; D M Stroka; M Nakamura; D W Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

View more
  14 in total

Review 1.  Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.

Authors:  Qiana L Matthews
Journal:  Mol Pharm       Date:  2010-12-01       Impact factor: 4.939

2.  Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Authors:  Wibke Bayer; Matthias Tenbusch; Ruth Lietz; Lena Johrden; Simone Schimmer; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

3.  Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice.

Authors:  Guohua Yi; Xiongying Tu; Preeti Bharaj; Hua Guo; Junli Zhang; Premlata Shankar; N Manjunath
Journal:  Mol Ther       Date:  2015-06-10       Impact factor: 11.454

4.  Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

Authors:  P A Kratz; B Böttcher; M Nassal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

5.  Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

Authors:  Aidy Salomon; Chavdar Krachmarov; Zhong Lai; William Honnen; Barry S Zingman; Julie Sarlo; Miroslaw K Gorny; Susan Zolla-Pazner; James E Robinson; Abraham Pinter
Journal:  Virology       Date:  2013-11-12       Impact factor: 3.616

Review 6.  Vaccine development against HIV-1: current perspectives and future directions.

Authors:  Rebecca L Edgeworth; Juan Homero San; Jason A Rosenzweig; Nang L Nguyen; Jean D Boyer; Kenneth E Ugen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

7.  Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity.

Authors:  S Crotty; B L Lohman; F X Lü; S Tang; C J Miller; R Andino
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

8.  Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].

Authors:  Mauro Lapelosa; Gail Ferstandig Arnold; Emilio Gallicchio; Eddy Arnold; Ronald M Levy
Journal:  J Mol Biol       Date:  2010-02-04       Impact factor: 5.469

9.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes.

Authors:  Mauro Lapelosa; Emilio Gallicchio; Gail Ferstandig Arnold; Eddy Arnold; Ronald M Levy
Journal:  J Mol Biol       Date:  2008-11-08       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.